Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals, Inc., a prominent player in the biopharmaceutical industry, is headquartered in the United States. Founded in 2005, the company has made significant strides in developing innovative therapies for patients with kidney disease, particularly focusing on conditions such as chronic kidney disease and end-stage renal disease. Keryx is best known for its flagship product, Auryxia (ferric citrate), which uniquely addresses both iron deficiency and hyperphosphataemia in patients undergoing dialysis. This dual-action capability sets Keryx apart in a competitive market. With a commitment to improving patient outcomes, Keryx has established a strong market position, recognised for its contributions to renal health. The company continues to expand its operational reach, aiming to enhance the quality of life for patients globally.
DitchCarbon Score
How does Keryx Biopharmaceuticals, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Keryx Biopharmaceuticals, Inc.'s score of 23 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Keryx Biopharmaceuticals, Inc.'s reported carbon emissions
Keryx Biopharmaceuticals, Inc., headquartered in the US, currently does not have publicly available carbon emissions data or specific climate commitments outlined in their reduction initiatives. As such, there are no reported figures for their carbon emissions, including Scope 1, 2, or 3 emissions. The absence of documented reduction targets or climate pledges suggests that Keryx may still be in the early stages of developing a comprehensive sustainability strategy. In the context of the biopharmaceutical industry, companies are increasingly focusing on reducing their carbon footprints and committing to science-based targets to mitigate climate change impacts. However, without specific data or commitments from Keryx, it is challenging to assess their current environmental performance or future climate strategies.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Keryx Biopharmaceuticals, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
